Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 16, 2012

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions
Adult Primary Hepatocellular CarcinomaLocalized Resectable Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver Cancer
Interventions
DRUG

sorafenib tosylate

Given PO

OTHER

placebo

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (21)

10016

New York University Langone Medical Center, New York

10065

New York Presbyterian-The University Hospital of Columbia and Cornell, New York

15213

University of Pittsburgh, Pittsburgh

20057

Lombardi Comprehensive Cancer Center at Georgetown University, Washington D.C.

30322

Emory University, Atlanta

37232

Vanderbilt University, Nashville

44195

Cleveland Clinic Foundation, Cleveland

48109

University of Michigan University Hospital, Ann Arbor

60611

Northwestern University, Chicago

70121

Ochsner Clinic Foundation, New Orleans

73112

Integris-Baptist Medical, Oklahoma City

77030

Baylor College of Medicine, Houston

The Methodist Hospital Research Institute, Houston

90095

Jonsson Comprehensive Cancer Center, Los Angeles

35294-0007

University of Alabama, Birmingham

80217-3364

University of Colorado, Denver

06112

Mount Sinai Hospital, Hartford

21287-8936

Johns Hopkins University, Baltimore

01805

Lahey Clinic Medical Center, Burlington

68198-7830

University of Nebraska Medical Center, Omaha

08034

University of Pennsylvania Health System, Cherry Hill

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER